Yolanda Real

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.

Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.

Journal: Hepatology (Baltimore, Md.)

Published: November 19, 2023

Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.

Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.

Journal: Journal of hepatology

Published: June 06, 2023

A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.

A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.

Journal: Hepatology (Baltimore, Md.)

Published: July 04, 2020

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.

Journal: Antiviral research

Published: April 15, 2019

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.

Journal: Journal of viral hepatitis

Published: July 26, 2016

Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.

Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.

Journal: Journal of viral hepatitis

Published: July 23, 2016

Ulcerative colitis associated with autoimmune pancreatitis, sialadenitis and leukocytoclastic vasculitis

Ulcerative colitis associated with autoimmune pancreatitis, sialadenitis and leukocytoclastic vasculitis

Journal: Gastroenterologia y hepatologia

Published: November 27, 2014

Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link.

Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link.

Journal: PloS one

Published: February 12, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026